Ronald Rubenstein, MD
Plastic Surgery within the Head & Neck · San Leandro, CANPI 1467568105
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,700 of the $9,072 with a category attached, or 95.9%. Regeneron accounts for 95.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $8,732 and has fallen 98.5% since, to $127 in 2024.
Across 21 payments — averaging $432.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$9K
- Intersect ENT, Inc.$79
- Stryker$71
- Smith+Nephew$50
- Optinose US, Inc.$43
- Sanofi$39
- plus $91 from 5 others
What the payments were for
- Consulting fees$8,70096%
- Food & beverage$3724%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 3 | $8,700 |
| Intersect ENT, Inc. | 4 | $79 |
| Stryker | 3 | $71 |
| Smith+Nephew | 2 | $50 |
| Optinose US, Inc. | 2 | $43 |
| Sanofi | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Cook Medical LLC | 1 | $21 |
| GSK | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Osiris Therapeutics Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$8,700
How this compares
$9,072 in reported general payments places this provider in the 85th percentile of 119 plastic surgery within the head & neck providers in California.
See all plastic surgery within the head & neck providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 63 | $3,187 |
| Omeprazole | 143 | $1,960 |
| Ipratropium Bromide | 31 | $1,334 |
| Levothyroxine Sodium | 32 | $1,003 |
| Famotidine | 54 | $682 |
| Pantoprazole Sodium | 18 | $415 |
| Fluticasone Propionate | 20 | $192 |
| Azithromycin | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Other plastic surgery within the head & neck in San Leandro
- William BinderBeverly Hills$136.4M
- Jivianne LeeSanta Monica$324K
- John JosephEncino$252K
- Rajesh ChopraBeverly Hills$75K
- Ronald KochMountain View$37K
- Rahul SethWalnut Creek$32K
- Yarah HaidarOrange$31K
- Amar GuptaRiverside$26K
- Donald YooBeverly Hills$12K
- Christopher ZoumalanBeverly Hills$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.